Discovery of novel and potent tacrine derivatives as CDK2 inhibitors-Reference-Cited by-同舟云学术

Discovery of novel and potent tacrine derivatives as CDK2 inhibitors

Published:2022 Issue:43 Volume:46 Page:20972-20984
ISSN:1144-0546
Container-title:New Journal of Chemistry
language:en
Short-container-title:New J. Chem.

Author:

Huang Yaoguang¹,Li Deping¹,Xu Chang¹,Zhu Chengze²,Wu Limeng¹,Shen Meiling³,Li Yue⁴,Jiang Xiaowen¹,Liu Wenwu¹,Zhao Qingchun¹²^ORCID,Ren Tianshu⁵

Affiliation:

1. Teaching Hospital of Shenyang Pharmaceutical University, General Hospital of Northern Theater Command, Shenyang 110840, People’s Republic of China

2. Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang, 110016, People's Republic of China

3. School of Life Sciences, Yunnan University, Kunming, 650091, People's Republic of China

4. School of Chemical Engineering, Sichuan University of Science & Engineering, 180 Xueyuan Street, Huixing Road, Zigong, Sichuan, 643000, People's Republic of China

5. Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People’s Republic of China

Abstract

After optimization of the lead compound, ZLHT-7, a compound with 10-fold higher selectivity for CDK2 over CDK9, was discovered.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

Materials Chemistry,General Chemistry,Catalysis

Link

http://pubs.rsc.org/en/content/articlepdf/2022/NJ/D2NJ03591J

Reference28 articles.

1. Proliferation, cell cycle and apoptosis in cancer

2. Cyclin-dependent kinases

3. Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer

4. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement

5. The history and future of targeting cyclin-dependent kinases in cancer therapy